10-K: Inotiv, Inc. Reports Fiscal Year 2024 Results Amidst NHP Market Volatility and Strategic Restructuring

Inotiv, Inc. faced significant challenges in fiscal year 2024, including decreased NHP sales and ongoing legal and regulatory issues, while also making progress on strategic restructuring and new service offerings.

Summary

• Inotiv, Inc. reported a decrease in revenue to $490.7 million for fiscal year 2024, down from $572.4 million in fiscal year 2023, primarily due to a significant decline in non-human primate (NHP) sales within the Research Models and Services (RMS) segment.
• The company experienced an increased operating loss of $86.4 million in fiscal year 2024, compared to $81.5 million in fiscal year 2023, driven by losses in the RMS segment and decreased operating income in the Discovery and Safety Assessment (DSA) segment.
• Net loss attributable to common shareholders increased to $108.4 million in fiscal year 2024, compared to $105.1 million in fiscal year 2023.
• The company's RMS segment revenue decreased by $76.7 million, primarily due to lower NHP sales, while the DSA segment revenue decreased by $5.0 million due to a decline in discovery services.
• Inotiv incurred $28.5 million in expenses related to a Resolution Agreement and Plea Agreement with the Department of Justice (DOJ) concerning a former canine breeding facility.
• The company has identified conditions that raise substantial doubt about its ability to continue as a going concern, including negative operating cash flows, operating losses, and net losses.
• Inotiv has taken steps to address these issues, including site optimization plans, new service offerings, and efforts to diversify NHP suppliers.
• The company has also amended its credit agreement to provide more flexibility in meeting financial covenants.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with significant revenue declines, increased losses, and a going concern warning. While there are some positive developments, the overall tone is negative due to the severity of the financial challenges and the ongoing legal and regulatory issues.

Positives

• The company completed its previously announced site optimization initiatives as of September 30, 2024.
• Inotiv has identified and extensively audited multiple additional sources of purpose-bred animals that can be made available for life-saving medical research.
• The company has amended its credit agreement to provide more flexibility in meeting financial covenants.
• The company has developed, and sourced, novel genetic testing techniques to further bolster its auditing capabilities to determine whether the animals we import are purpose-bred.
• The company is assessing the ability to introduce these techniques into its supply chain.
• The company experienced improvements in revenue and operating results in the fourth fiscal quarter of 2024 as compared to the second and third fiscal quarters of 2024.

Negatives

• Inotiv's revenue decreased to $490.7 million in fiscal year 2024, down from $572.4 million in fiscal year 2023.
• The company's operating loss increased to $86.4 million in fiscal year 2024, compared to $81.5 million in fiscal year 2023.
• Net loss attributable to common shareholders increased to $108.4 million in fiscal year 2024, compared to $105.1 million in fiscal year 2023.
• RMS segment revenue decreased by $76.7 million, primarily due to lower NHP sales.
• DSA segment revenue decreased by $5.0 million due to a decline in discovery services.
• The company incurred $28.5 million in expenses related to a Resolution Agreement and Plea Agreement with the DOJ.
• Inotiv has identified conditions that raise substantial doubt about its ability to continue as a going concern.

Risks

• The company's dependence on the importation of NHPs from outside the U.S., particularly from communist countries in Southeast Asia, poses a significant risk.
• Legal issues related to NHP suppliers and any inability to diversify suppliers could adversely affect the company.
• The company has identified conditions and events that could raise substantial doubt about its ability to continue as a going concern.
• The company has experienced periods of losses and financial insecurity.
• The company has incurred significant additional indebtedness, which may impair its ability to raise further capital or impact its ability to service its debt.
• The company's credit agreement contains covenants that restrict its business and financing activities.
• The company's failure to comply with the terms of its credit agreement could result in an event of default.
• The company may need additional capital, and any additional capital it seeks may not be available in the amount or at the time it needs it.
• The company's management concluded that its disclosure controls and procedures and its internal control over financial reporting were not effective as of September 30, 2024 and 2023 due to material weaknesses.
• The company is involved in legal proceedings that could adversely affect its business, financial condition, and results of operations.
• The company is subject to inspections, investigations and enforcement actions by regulatory authorities, which could lead to penalties.
• The company is subject to environmental, health and safety requirements and risks.
• Changes in government regulation or in practices relating to the pharmaceutical industry could decrease the demand for the services the company provides.
• If the company fails to comply with data privacy and security laws and regulations, it could face substantial penalties.
• The company relies on a limited number of key clients, and a loss of one or more of these key clients may adversely affect its operating results.
• The company operates in a highly competitive industry.
• The majority of the company's client contracts and orders can be terminated upon short notice.
• The company may bear financial risk if it underprices its contracts or overruns cost estimates.
• The company's business uses biological and hazardous materials, which could injure people or violate laws.
• The company's animal populations may suffer diseases that can damage its inventory.
• Failure to manage growth effectively could cause the company's business to suffer.
• Providing contract research services creates a risk of liability.
• New technologies may be developed that could reduce demand for some of the company's products and services.
• The company's non-U.S. operations expose it to risks associated with operating internationally.
• Some of the company's clients and contracts depend on government funding of research and development.
• The company has and may further expand its business through acquisitions, which exposes it to various risks.
• The company may fail to realize anticipated strategic and financial benefits from acquisitions.
• The company is substantially dependent on the pharmaceutical and biotechnology industries.
• The company's future success may depend on its ability to keep pace with rapid technological changes.
• Actions of animal rights activists may affect the company's business.
• The company is at risk of cyber-attacks or other security breaches.
• Hardware or software failures could harm the company's business.
• The company's share price could continue to be volatile.
• The resale of certain common shares underlying warrants could adversely affect the market price of the company's common shares.
• Anti-takeover provisions in the company's organizational documents and under Indiana law may discourage or prevent a change in control.
• If the company is unable to maintain listing of its securities on The Nasdaq Capital Market, it may be more difficult for its shareholders to sell their securities.

Future Outlook

The company plans to continue its efforts to optimize its capital allocation and expense base, improve operating results through increased NHP sales and discovery and safety assessment contract awards, and continue discussions with its lenders. The company also intends to initiate the next phase of its site optimization program to further improve and consolidate additional RMS facilities in the U.S.

Management Comments

• Management believes that it has identified the appropriate supply of NHPs to meet forecasted demand for fiscal 2025.
• Management believes that it can achieve another $500 to $1,000 in cost reductions from the continued integration of its North American transportation and distribution system.
• Management's fiscal 2025 annual operating plan forecasts compliance with its recently updated financial covenants pursuant to the Seventh Amendment to the Credit Agreement.

Industry Context

The company operates in the highly competitive contract research services industry, which is experiencing consolidation. The company's performance is affected by trends in the pharmaceutical and biotechnology industries, including outsourcing, funding levels, and regulatory changes. The limited availability of NHPs has also impacted the industry, leading to increased costs and shifts in study locations.

Comparison to Industry Standards

• The company's financial results are below industry standards, particularly in terms of profitability and revenue growth.
• The company's operating loss and net loss are significantly higher than those of comparable companies in the CRO sector.
• The company's reliance on NHP sales makes it more vulnerable to market fluctuations than companies with more diversified revenue streams.
• The company's debt levels are higher than those of many of its competitors, which increases its financial risk.
• The company's internal control weaknesses are a concern, as they could lead to inaccurate financial reporting.
• The company's legal and regulatory issues are also a significant risk, as they could result in penalties and reputational damage.
• The company's performance is worse than that of Charles River Laboratories, a major competitor in the CRO industry, which has reported consistent revenue growth and profitability.
• The company's performance is also worse than that of WuXi AppTec, a Chinese CRO, which has reported strong revenue growth and profitability.
• The company's performance is also worse than that of Envigo, a former competitor, which was acquired by the company in 2021.

Management Changes

Legal Proceedings

• The company is involved in legal proceedings related to various matters, including employment and securities litigation.
• A putative securities class action and derivative securities lawsuits have been filed against the Company and certain officers and directors, alleging, among other things, violations of the Exchange Act related to the Companys disclosures concerning its acquisitions of Envigo and OBRC and their regulatory compliance.
• The company is subject to periodic inspections by regulatory authorities, including the FDA, the USDA and the U.S. Fish and Wildlife Service.
• The company is subject to federal, state and foreign healthcare and other regulations, including anti-bribery and anti-corruption laws.

Related Party Transactions

• The company has a Seller Note with Bolder BioPath, a related party.
• The company has a Seller Note with Histion, a related party.
• The company has a Seller Note with Protypia, a related party.

Stakeholder Impact

• Shareholders are negatively impacted by the decreased revenue, increased losses, and the going concern warning.
• Employees may be affected by the site optimization plans and potential restructuring.
• Customers may be affected by the company's ability to provide consistent and reliable services due to the NHP supply issues and regulatory challenges.
• Suppliers may be affected by the company's financial difficulties and potential restructuring.
• Creditors are at risk due to the company's high debt levels and potential default on its credit agreement.

Next Steps

• The company intends to initiate the next phase of its site optimization program to further improve and consolidate additional RMS facilities in the U.S.
• The company plans to continue its efforts to improve its operating results through increases to its NHP-related product and service revenue.
• The company plans to continue its efforts to improve its operating results through increasing purchase orders for long-term colony management service contracts.
• The company plans to continue its efforts to improve its operating results through increasing its volume of discovery and safety assessment contract awards.
• The company also continues to discuss its current business conditions with its lenders.

Key Dates

Keywords

Non-human primates, NHP, Contract research organization, CRO, Drug discovery, Drug development, Preclinical research, Safety assessment, Research models, Animal welfare, Biotechnology, Pharmaceutical, Financial results, Regulatory compliance, Site optimization